Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Front Endocrinol (Lausanne). 2022 Mar 4;13:858332. doi: 10.3389/fendo.2022.858332. eCollection 2022.
Although a finding of isolated elevated thyrotropin (TSH) often leads to treatment with thyroid hormone, it is not specific to a diagnosis of subclinical hypothyroidism, particularly in older adults. We have previously used longitudinal assessment of TSH and free thyroxine (FT4) to distinguish primary and secondary changes in the hypothalamic-pituitary-thyroid (HPT) axis, an approach which is impractical for clinical diagnosis.
Identify contemporaneous clinical tests and criteria that predict the longitudinally-derived HPT axis phenotype in those with isolated elevated TSH.
Using data from Baltimore Longitudinal Study of Aging, participants with over three years of follow up not on thyroid hormone replacement, with a TSH above the reference range and an in-range FT4 at the current visit, and at least 1% per year increase in TSH (mean 6.9% annual increase; n=72), we examined correlations between various clinical factors and the change in FT4 across the phenotypic range from emerging hypothyroidism, with falling FT4, to adaptive stress-response, with rising FT4.
Current FT4 level, but not TSH, Free T3, anti-TPO antibody status, age or sex, was significantly associated with phenotype, determined by the annual rate of change in FT4 in those with elevated and rising TSH, both as a continuous variable (β=0.07 per ng/dL increase in FT4; p<0.001) and in quartiles (p<0.001). We estimated a threshold for FT4 of less than 0.89 ng/dL (11.45 pmol/L; the 24 percentile of the reference range), as predictive of a phenotype in the first quartile, consistent with subclinical hypothyroidism, while a FT3:FT4 ratio below 2.77 predicted a phenotype in the fourth quartile, more consistent with adaptive stress-response.
In those with isolated elevated TSH, a FT4 in the lowest quartile of the reference range differentiates those with developing hypothyroidism from other HPT-axis aging changes.
尽管孤立性促甲状腺激素(TSH)升高的发现通常导致甲状腺激素治疗,但它并不特异于亚临床甲状腺功能减退症的诊断,尤其是在老年人中。我们之前曾使用 TSH 和游离甲状腺素(FT4)的纵向评估来区分下丘脑-垂体-甲状腺(HPT)轴的原发性和继发性变化,这种方法对于临床诊断来说并不实用。
确定同时存在的临床检测和标准,以预测孤立性 TSH 升高患者中纵向 HPT 轴表型。
使用巴尔的摩纵向衰老研究的数据,对超过三年随访、未服用甲状腺激素替代治疗、TSH 高于参考范围且当前就诊时 FT4 在范围内、且 TSH 每年增加 1%以上(平均每年增加 6.9%;n=72)的患者,我们检查了各种临床因素与从新发甲状腺功能减退症(FT4 下降)到适应性应激反应(FT4 升高)的表型范围内 FT4 变化之间的相关性。
当前 FT4 水平,而不是 TSH、游离 T3、抗甲状腺过氧化物酶抗体状态、年龄或性别,与表型显著相关,这是通过 TSH 升高和持续升高患者的 FT4 年变化率来确定的,无论是作为连续变量(β=0.07 每 ng/dL FT4 增加;p<0.001)还是四分位数(p<0.001)。我们估计 FT4 低于 0.89 ng/dL(11.45 pmol/L;参考范围的第 24 百分位)的阈值可预测第一四分位数的表型,与亚临床甲状腺功能减退症一致,而 FT3:FT4 比值低于 2.77 则预测第四四分位数的表型,更符合适应性应激反应。
在孤立性 TSH 升高的患者中,参考范围最低四分位的 FT4 将那些发展为甲状腺功能减退症的患者与其他 HPT 轴老化变化区分开来。